Skip to main content

Research

Since its foundation, the Institut Jules Bordet has always strived to understand the cellular mechanisms involved in cancer and to improve cancer treatments. By collaborating closely with healthcare professionals and doctors from all fields of medicine, researchers at the Institut Bordet are able to offer patients the latest innovations derived from scientific research.

«The projects carried out by researchers at the Institut Bordet are exceptional in their cross-disciplinary nature and inventiveness. Driving healthcare forward and exploring all possible research avenues – this is the approach we take at the Institut Bordet. » 
   

Martine Piccart 
Research Director

Title
How research helps to move cancer treatment forward

Paragraph body
At the Institut Jules Bordet, research is both clinical and translational. It is a highly organised activity mobilising and involving numerous health professionals, as well as patients.

Clinical Research

The term clinical research encompasses the studies and clinical trials that we carry out at the Institut Jules Bordet with our partners, academic research centres and pharmaceutical companies. The aims of these studies include:  

  • testing new diagnostic techniques;
  • comparing a number of different therapeutic strategies;
  • testing new and innovative medicines, particularly for cancers where no effective treatment currently exists.

Clinical research is only possible with patient involvement. Patient participation in clinical trials enables researchers to answer important research questions. 

Recherche Clinique

Translational Research

The principal roles of translational research are to understand cancer and identify markers that will assist in diagnosis, in predicting response to certain treatments and in patient prognosis. This type of research is based on the analysis of the blood and/or tumour samples that are removed, with the patient’s consent, during diagnosis or treatment. As an integral part of clinical research, the aim of translational research is to transform these findings rapidly into concrete options in the care offered to patients.

recherche translationnelle

Conducting and organising clinical research

The Institut Jules Bordet participates in cancer research by running clinical trials designed by its researchers and by other research groups across the world. A number of bodies are involved in the organisation and running of clinical trials:

Collaboration for innovation

Research is always a collaborative activity, particularly so in the field of cancer. In order to explore the most promising avenues, the Institut Jules Bordet works together with other academic and/or private bodies.
 

Academic Partners

Academic research is in the very DNA of the Institut Jules Bordet. Indeed, some prestigious research networks began their life here, including the EORTC, the BIG and, more recently the Oncodistinct network. Offering the best care for each patient is a complicated matter, given the complexity and diversity of their situations and the range of possible therapeutic strategies available. Therefore, medical staff need to question their practice rigorously, in particular by means of clinical trials. These trials take place in a university framework. Their results often have a significant and positive impact on the care offered to patients.

Private Partners

To find new drugs and new medical equipment for its patients, the Institut Jules Bordet supports and collaborates with those developing innovative treatments: pharmaceutical companies. Some clinical trials at the Institut Bordet are therefore carried out in partnership with these companies and always with the patient’s best interests in mind.

Title
Taking part in the fight against cancer

Clinical Trials

As a patient, you may be invited to take part in a clinical trial of a new treatment, a new medical investigation technique or an innovative approach to care. In addition to the benefits this may bring you personally, taking part in a clinical trial contributes to the advancement of medicine and helps future patients.

However, your participation in these studies is strictly voluntary, not obligatory. No research procedures will ever be carried out without your agreement. To help you decide with full knowledge of the facts and give what is called “informed patient consent”, you will receive comprehensive information verbally and in writing. Your referring physician will explain to you as fully and clearly as possible the potential risks and benefits of taking part in the clinical trial you have been offered.

Your health and your quality of life are our primary concern. If your health requires it, or if you so choose, you may end your participation in the clinical trial at any time.

Choosing to participate in a clinical trial

 

Clinical Trials

Find a clinical trial

Professionals, join us in the fight against cancer!

 Scientific publications

Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU.

Authors : Pistone A, Durieux V, Grigoriu B, Meert AP
Year : 2019
Journal : J Intensive Care Med
Volume : 34
Pages : 435-448

Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.

Authors : Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I
Year : 2019
Journal : Cancer Treat Rev
Volume : 72
Pages : 65-77

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.

Authors : Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 134

Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.

Authors : Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Rouprêt M, de La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ
Year : 2019
Journal : J Urol
Volume : 202
Pages : 725-731

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.

Authors : Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1148-1159